Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Gastroenterology
Published in: Current Treatment Options in Gastroenterology 4/2019

01-12-2019 | Shingles | Gastroenterology for Geriatric Patients (S Katz and A Afzali, Section Editors)

Vaccination in the Elderly and IBD

Authors: Anthony J. Choi, MD, Preston Atteberry, MD, Dana J. Lukin, MD, PhD

Published in: Current Treatment Options in Gastroenterology | Issue 4/2019

Login to get access

Abstract

Purpose of review

Significant gaps in knowledge and utilization of vaccinations exist among practitioners providing care for patients with IBD. This review is intended to update the reader on best practices for vaccination within the IBD population with a specific focus on the elderly.

Recent findings

Advances in IBD therapeutics have recently increased the number of immunosuppressive therapies available to practitioners. Differences in mechanisms of action of these medications have led to differential implications pertaining to vaccination strategies. Additionally, new vaccines, including the recombinant zoster vaccine, have recently become available for the use in the IBD population.

Summary

Given the prominent role the IBD provider plays in the management of patients with IBD, a clear understanding of best practices is essential. This review provides a framework for the integration of optimal vaccination strategies for practitioners caring for adult and elderly patients with IBD.
Literature
1.
Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390(10114):2769–78.
2.
Gisbert JP, Chaparro M. Systematic review with meta-analysis: inflammatory bowel disease in the elderly. Aliment Pharmacol Ther. 2014;39(5):459–77.PubMed
3.
Hussain SW, Pardi DS. Inflammatory bowel disease in the elderly. Drugs Aging. 2010;27(8):617–24.PubMed
4.
Loftus EV, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut. 2000;46(3):336–43.CrossRefPubMedPubMedCentral
5.
• Selby L, Kane S, Wilson J, et al. Receipt of preventive health services by IBD patients is significantly lower than by primary care patients. Inflamm Bowel Dis. 2008;14(2):253–8 This study identified gaps in the receipt of routine preventive care, including vaccinations, within the IBD population.PubMed
6.
Selby L, Hoellein A, Wilson JF. Are primary care providers uncomfortable providing routine preventive care for inflammatory bowel disease patients? Dig Dis Sci. 2011;56(3):819–24.PubMed
7.
Wasan SK, Coukos JA, Farraye FA. Vaccinating the inflammatory bowel disease patient: deficiencies in gastroenterologists knowledge. Inflamm Bowel Dis. 2011;17(12):2536–40.PubMed
8.
Yeung JH, Goodman KJ, Fedorak RN. Inadequate knowledge of immunization guidelines: a missed opportunity for preventing infection in immunocompromised IBD patients. Inflamm Bowel Dis. 2012;18(1):34–40.PubMed
9.
Castle SC. Clinical relevance of age-related immune dysfunction. Clin Infect Dis. 2000;31(2):578–85.PubMed
10.
• Ciabattini A, Nardini C, Santoro F, Garagnani P, Franceschi C, Medaglini D. Vaccination in the elderly: the challenge of immune changes with aging. Semin Immunol. 2018;40:83–94 This article describes differnences in the immune response to vaccination among elderly patients.PubMed
11.
Gecse KB, Lakatos PL. IBD in 2016: biologicals and biosimilars in IBD - the road to personalized treatment. Nat Rev Gastroenterol Hepatol. 2017;14(2):74–6.PubMed
12.
Viget N, Vernier-Massouille G, Salmon-Ceron D, Yazdanpanah Y, Colombel JF. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut. 2008;57(4):549–58.PubMed
13.
• Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. Gastroenterology. 2018;155(2):337–346.e10 Synopsis of infectious risk among patients with IBD. This frames the need for preventive vaccination in this population.
14.
Lopez A, Mariette X, Bachelez H, et al. Vaccination recommendations for the adult immunosuppressed patient: a systematic review and comprehensive field synopsis. J Autoimmun. 2017;80:10–27.PubMed
15.
16.
Chow EJ, Davis CT, Abd Elal AI, et al. Update: influenza activity - United States and worldwide, May 20-October 13, 2018. MMWR Morb Mortal Wkly Rep. 2018;67(42):1178–85.PubMedPubMedCentral
17.
Meites E; Kempe A, Markowitz LE. Use of a 2-dose schedule for human papilloma virus vaccination - updated recommendations of the Advisory Committee on Immunization Practices. MMWR 2016; 65(49);1405–1408PubMed
18.
19.
•• Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol. 2017;112(2):241–58 This important guideline details best practices for preventive care within the IBD patient population with an in-depth description of vaccine recommendations.PubMed
20.
Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):e44–100.PubMed
21.
Rahier J-F, Papay P, Salleron J, et al. H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut. 2011;60(4):456–62.PubMed
22.
Dotan I, Werner L, Vigodman S, et al. Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines. Inflamm Bowel Dis. 2012;18(2):261–8.PubMed
23.
Agarwal N, Ollington K, Kaneshiro M, Frenck R, Melmed GY. Are immunosuppressive medications associated with decreased responses to routine immunizations? A systematic review. Vaccine. 2012;30(8):1413–24.PubMed
24.
Loubet P, Verger P, Abitbol V, Peyrin-Biroulet L, Launay O. Pneumococcal and influenza vaccine uptake in adults with inflammatory bowel disease in France: results from a web-based study. Dig Liver Dis. 2018;50(6):563–7.PubMed
25.
Melmed GY, Ippoliti AF, Papadakis KA, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006;101(8):1834–40.PubMed
26.
Malhi G, Rumman A, Thanabalan R, et al. Vaccination in inflammatory bowel disease patients: attitudes, knowledge, and uptake. J Crohns Colitis. 2015;9(6):439–44.PubMed
27.
Parker S, Chambers White L, Spangler C, et al. A quality improvement project significantly increased the vaccination rate for immunosuppressed patients with IBD. Inflamm Bowel Dis. 2013;19(9):1809–14.PubMed
28.
Reich JS, Miller HL, Wasan SK, et al. Influenza and pneumococcal vaccination rates in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2015;11(6):396–401.
29.
Kasper AK, Pallotta AM, Kovacs CS, Spinner ML. Infectious diseases consult improves vaccination adherence in kidney transplant candidates. Vaccine. 2018;36(34):5112–5.PubMed
30.
Gisbert JP, Chaparro M. Vaccination strategies in patients with IBD. Nat Rev Gastroenterol Hepatol. 2013;10(5):277–85.PubMed
31.
Long MD, Martin C, Sandler RS, Kappelman MD. Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37(4):420–9.PubMed
32.
Kim DK, Riley LE, Hunter P. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older - United States, 2018. MMWR Morb Mortal Wkly Rep. 2018;67(5):158–60.PubMedPubMedCentral
33.
Narula N, Yamamura DLR, Marshall JK. Should my patient with inflammatory bowel disease on immunosuppressive therapy be vaccinated against influenza virus? Can J Gastroenterol. 2010;24(2):121–5.PubMedPubMedCentral
34.
Chang JY, Jung S-A, Moon CM, Kim S-E, Jung H-K, Shim K-N. Response to hepatitis B vaccination in patients with inflammatory bowel disease: a prospective observational study in Korea. Intest Res. 2018;16(4):599–608.PubMedPubMedCentral
35.
• Pratt PK, David N, Weber HC, et al. Antibody response to hepatitis B virus vaccine is impaired in patients with inflammatory bowel disease on infliximab therapy. Inflamm Bowel Dis. 2018;24(2):380–6 This recent study highlights the potential adverse impact of TNF antagonist therapy on the immunogenicity of the hepatitis B vaccine in the IBD population.PubMed
36.
Gisbert JP, Villagrasa JR, Rodríguez-Nogueiras A, Chaparro M. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol. 2012;107(10):1460–6.PubMed
37.
Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part II: immunization of adults. MMWR Recomm Rep. 2006;55(RR-16):1–33 quiz CE1.
38.
Andrade P, Santos-Antunes J, Rodrigues S, Lopes S, Macedo G. Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients. J Gastroenterol Hepatol. 2015;30(11):1591–5.PubMed
39.
Cleveland NK, Rodriquez D, Wichman A, Pan I, Melmed GY, Rubin DT. Many inflammatory bowel disease patients are not immune to measles or pertussis. Dig Dis Sci. 2016;61(10):2972–6.PubMed
40.
Caldera F, Misch EA, Saha S, et al. Immunosuppression does not affect antibody concentrations to measles, mumps, and rubella in patients with inflammatory bowel disease. Dig Dis Sci. 2019;64(1):189–95.PubMed
41.
Andrisani G, Frasca D, Romero M, et al. Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: effects of combined therapy with immunosuppressants. J Crohns Colitis. 2013;7(4):301–7.PubMed
42.
Gelinck LBS, van der Bijl AE, Beyer WEP, et al. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis. 2008;67(5):713–6.PubMed
43.
Hagihara Y, Ohfuji S, Watanabe K, et al. Infliximab and/or immunomodulators inhibit immune responses to trivalent influenza vaccination in adults with inflammatory bowel disease. J Crohns Colitis. 2014;8(3):223–33.PubMed
44.
Lu Y, Bousvaros A. Immunizations in children with inflammatory bowel disease treated with immunosuppressive therapy. Gastroenterol Hepatol (N Y). 2014;10(6):355–63.
45.
Mamula P, Markowitz JE, Piccoli DA, Klimov A, Cohen L, Baldassano RN. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5(7):851–6.PubMed
46.
deBruyn JCC, Hilsden R, Fonseca K, et al. Immunogenicity and safety of influenza vaccination in children with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(1):25–33.PubMed
47.
Cullen G, Bader C, Korzenik JR, Sands BE. Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease. Gut. 2012;61(3):385–91.PubMed
48.
Nguyen DL, Nguyen ET, Bechtold ML. Effect of immunosuppressive therapies for the treatment of inflammatory bowel disease on response to routine vaccinations: a meta-analysis. Dig Dis Sci. 2015;60(8):2446–53.PubMed
49.
deBruyn J, Fonseca K, Ghosh S, et al. Immunogenicity of influenza vaccine for patients with inflammatory bowel disease on maintenance infliximab therapy: a randomized trial. Inflamm Bowel Dis. 2016;22(3):638–47.PubMed
50.
• Melmed GY. Vaccinations while on thiopurines: some protection is better than none. Am J Gastroenterol. 2012;107(1):141–2 This study demonstrates that despite numerous studies demonstrating a blunted immune response to vaccinations among patients with IBD receiving thiopurine immunosuppression, the diminished immune response is still likely sufficient to provide protection against illness, including with influenza.PubMed
51.
Beaulieu DB, Ananthakrishnan AN, Martin C, Cohen RD, Kane SV, Mahadevan U. Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines. Clin Gastroenterol Hepatol. 2018;16(1):99–105.PubMed
52.
Julsgaard M, Christensen LA, Gibson PR, et al. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. Gastroenterology. 2016;151(1):110–9.PubMed
53.
Brogan MD, Shanahan F, Oliver M, Stevens RH, Targan SR. Defective memory B cell formation in patients with inflammatory bowel disease following tetanus toxoid booster immunization. J Clin Lab Immunol. 1987;24(2):69–74.PubMed
54.
Nielsen HJ, Mortensen T, Holten-Andersen M, Brünner N, Sørensen S, Rask-Madsen J. Increased levels of specific leukocyte- and platelet-derived substances during normal anti-tetanus antibody synthesis in patients with inactive Crohn disease. Scand J Gastroenterol. 2001;36(3):265–9.PubMed
55.
Rüddel J, Schleenvoigt BT, Schüler E, Schmidt C, Pletz MW, Stallmach A. Yellow fever vaccination during treatment with infliximab in a patient with ulcerative colitis: a case report. Z Gastroenterol. 2016;54(9):1081–4.PubMed
56.
Ekenberg C, Friis-Møller N, Ulstrup T, Aalykke C. Inadvertent yellow fever vaccination of a patient with Crohn’s disease treated with infliximab and methotrexate. BMJ Case Rep. 2016;2016.
57.
Toruner M, Loftus EV, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134(4):929–36.PubMed
58.
Osterman MT, Haynes K, Delzell E, et al. Effectiveness and safety of immunomodulators with anti-tumor necrosis factor therapy in Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13(7):1293–1301.e5 quiz e70, e72.PubMedCentral
59.
• Khan N, Vallarino C, Lissoos T, Darr U, Luo M. Risk of infection and types of infection among elderly patients with inflammatory bowel disease: a retrospective database analysis. Inflamm Bowel Dis 2019. This large retrospective Truven database study identified an increased risk of pneumonia and sepsis among elderly patients with IBD as compared to those aged 18-64.
60.
Ananthakrishnan AN, McGinley EL. Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. J Crohns Colitis. 2013;7(2):107–12.PubMed
61.
• Kantsø B, Simonsen J, Hoffmann S, Valentiner-Branth P, Petersen AM, Jess T. Inflammatory bowel disease patients are at increased risk of invasive pneumococcal disease: a nationwide Danish cohort study 1977-2013. Am J Gastroenterol. 2015;110(11):1582–7 This study highlights the increased risk of invasive pneumococcal infection within patients with IBD and therefore the importance of proactive immunization in the immunosuppressed population.PubMed
62.
Melmed GY, Agarwal N, Frenck RW, et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105(1):148–54.PubMed
63.
Fiorino G, Peyrin-Biroulet L, Naccarato P, et al. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2012;18(6):1042–7.PubMed
64.
van Aalst M, Garrido HMG, van der Leun J, et al. Immunogenicity of the currently recommended pneumococcal vaccination schedule in patients with inflammatory bowel disease. Clin Infect Dis 2019;
65.
Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7(8):874–81.PubMedPubMedCentral
66.
Schmader K. Herpes zoster in older adults. Clin Infect Dis. 2001;32(10):1481–6.PubMed
67.
Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341–9.PubMed
68.
Khan N, Patel D, Trivedi C, et al. Overall and comparative risk of herpes zoster with pharmacotherapy for inflammatory bowel diseases: a nationwide cohort study. Clin Gastroenterol Hepatol. 2018;16(12):1919–1927.e3.PubMed
69.
Nugent Z, Singh H, Targownik LE, Bernstein CN. Herpes zoster infection and herpes zoster vaccination in a population-based sample of persons with IBD: is there still an unmet need? Inflamm Bowel Dis. 2019;25(3):532–40.PubMed
70.
Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012;308(1):43–9.PubMedPubMedCentral
71.
Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA. 2013;309(9):887–95.PubMedPubMedCentral
72.
Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710.PubMed
73.
Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711–21.PubMed
74.
Meserve J, Aniwan S, Koliani-Pace JL, et al. Retrospective analysis of safety of vedolizumab in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2018; 17(8):1533-1540.e2PubMed
75.
Schreiber S, Dignass A, Peyrin-Biroulet L, et al. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. J Gastroenterol. 2018;53(9):1048–64.PubMedPubMedCentral
76.
Lukin DJ, Weiss A, Aniwan S, et al. 277 - Comparative safety profile of vedolizumab and tumor necrosis factor-antagonist therapy for inflammatory bowel disease: a multicenter consortium propensity score-matched analysis. Gastroenterology. 2018;154(6):S-68.
77.
Schreiber S, Peyrin-Biroulet L, Loftus EV, et al. OP34 VARSITY: a double-blind, double-dummy, randomised, controlled trial of vedolizumab versus adalimumab in patients with active ulcerative colitis. J Crohn's Colitis. 2019;13(Supplement_1):S612–3.
78.
Adar T, Faleck D, Sasidharan S, et al. Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study. Aliment Pharmacol Ther. 2019;49(7):873–9.PubMedPubMedCentral
79.
Navaneethan U, Edminister T, Zhu X, Kommaraju K, Glover S. Vedolizumab is safe and effective in elderly patients with inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(4):E17.PubMed
80.
Harrington JE, Hamilton RE, Wasan SK, Farraye FA, Ganley-Leal L. Immunogenicity of the influenza vaccine in IBD patients treated with vedolizumab. American Journal of Gastroenterology 2018;113(Supplement):S407–8.
81.
• Wyant T, Leach T, Sankoh S, et al. Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut. 2015;64(1):77–83. Vedolizumab as a gut-selective lymphocyte trafficking inhibitor which does not cause systemic immunosuppression. This study shows that immunogenicity to oral antigens but not parenterally administered antigens is impaired by vedolizumab. The “gut-selectivity” leads to preserved systemic immune function, leading to the recommendation that live parenteral vaccines will not place patients at risk for infection.PubMed
82.
83.
84.
• Reich J, Pei-Hsuan L, Zahorian T, Noronha A, Wasan SK, Farraye FA. P2231 - use of recombinant zoster vaccine (RZV-Shingrix) in patients with inflammatory bowel disease. ACG 2018 Annual Scientific Meeting Abastracts 2018 ;This is the first report of the use of the recombinant zoster vaccine among patients with IBD. While the size was limited, immunogenicity appears comparable with the general population.
85.
Winthrop KL, Melmed GY, Vermeire S, et al. Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel Dis. 2018;24(10):2258–65.PubMedPubMedCentral
86.
Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723–36.PubMed
87.
Sandborn WJ, Panés J, D’Haens GR, et al. Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials. Clin Gastroenterol Hepatol. 2018;17(8):1541–50.PubMed
88.
89.
Metadata
Title
Vaccination in the Elderly and IBD
Authors
Anthony J. Choi, MD
Preston Atteberry, MD
Dana J. Lukin, MD, PhD
Publication date
01-12-2019
Publisher
Springer US
Published in
Current Treatment Options in Gastroenterology / Issue 4/2019
Print ISSN: 1092-8472
Electronic ISSN: 1534-309X
DOI
https://doi.org/10.1007/s11938-019-00257-y

Other articles of this Issue 4/2019

Current Treatment Options in Gastroenterology 4/2019 Go to the issue

Genetics in Gastroenterology Practice (B Katona, Section Editor)

Pancreatic Cancer Surveillance: Who, When, and How

Genetics in Gastroenterology Practice (B Katona, Section Editor)

Hereditary Polyposis Syndromes

Nutrition and Obesity (O Pickett-Blakely, Section Editor)

Popular Diet Trends for Inflammatory Bowel Diseases: Claims and Evidence

Genetics in Gastroenterology Practice (B Katona, Section Editor)

Genetic testing for hereditary gastrointestinal cancer syndromes: Interpreting results in today's practice

Genetics in Gastroenterology Practice (B Katona, Section Editor)

Incorporating Colorectal Cancer Genetic Risk Assessment into Gastroenterology Practice

Gastroenterology for Geriatric Patients (S Katz and A Afzali, Section Editors)

Sleep Disturbances in the Elderly Patient with Inflammatory Bowel Disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits